Birla Opus Files Antitrust Complaint Against Asian Paints Market Showdown Likely
On June 6, 2025, Birla Opus, the paint division of India’s Aditya Birla Group, filed an antitrust complaint against industry leader Asian Paints, accusing it of abusing its market dominance, according to three sources familiar with the matter.
Asian Paints, which holds a 52% market share according to Elara Capital, has seen its dominance challenged by the rapid rise of Birla Opus, which captured 7% of the market just a year after its February 2024 IPO.
The complaint, filed with the Competition Commission of India (CCI), alleges that Asian Paints pressured retail distributors to avoid selling rival products, warning them of credit restrictions if they stocked Birla Opus paints. Additionally, distributors were allegedly told they could face supply cuts if they prominently displayed Birla Opus ads or products.
The CCI has yet to decide whether to open a full investigation or dismiss the case. A source revealed that Asian Paints has denied the allegations in a confidential letter to the CCI, arguing that Birla Opus' rapid growth proves no anti-competitive barriers exist in the market.
This is not the first time Asian Paints has faced scrutiny. In 2022, the CCI dismissed similar allegations from JSW Paints, ruling no violation of competition laws.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF India to Shut Two Dahej Care Chemicals Plants as Overcapacity Squeezes Margins
-
LANXESS Specialty Additives Earnings Jump 32.8%, but Chemical Demand Recovery Remains Elusive
-
BASF Brings Biomass-Balance Polyols to North America
-
Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard
-
Wanhua Chemical's Hungarian 650,000-ton MDI/TDI Plant to Shut Down for 35-Day Maintenance
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
Recommend Reading
-
BASF Sues Apple Over Face Authentication Patents Used in Dozens of iPhones and iPads
-
Kering and L'Oréal Form $4 Billion Strategic Alliance in Luxury Beauty and Wellness
-
BASF Raises Acid Chloride and Chloroformate Capacity by 30% at Ludwigshafen
-
SABIC Agri-Nutrients Advances Mega Fertilizer Expansion With 1.2 Million MT/Year Ammonia Plant
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Business Society October 12, 2026 Ammonium Sulfate Trend Analysis: Clearly Downward
-
Business Society’s Market Outlook for Hydrofluoric Acid on September 1, 2026: Price Trend Is Volatile (Tending to Rise)
-
Business Society’s MTBE Market Outlook on August 28, 2026: Volatile Consolidation
-
Business Society October 12, 2026 Melamine Trend Analysis: Strong Rebound
-
Cost Support: Adipic Acid Sees Rising Prices